MedTrace Logo

Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

NCT05154123 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-02-25

No results posted yet for this study

Summary

Drug-drug interaction study of rosuvastatin and AT-527 (R07496998)

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

Drug: AT-527 + rosuvastatin

* Day 1: A single dose of rosuvastatin will be administered. * Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.

DRUG

AT-527 + rosuvastatin

* Day 1: A single dose of rosuvastatin will be administered. * Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2021-12-23
Completion
2021-12-23
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05154123 on ClinicalTrials.gov